J&J Risperdal “Not Approvable” For Autism, Alzheimer’s Psychosis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson is considering how to proceed with Risperdalafter two supplemental applications for new indications for the atypical antipsychotic have been deemed "not approvable" by FDA
You may also be interested in...
Namenda "not approvable" for mild-moderate Alzheimer’s
Forest's Namenda (memantine) is "not approvable" for treatment of mild-to-moderate Alzheimer's disease, the firm says July 25. Two studies failing to show statistical significance led FDA to deny the indication. The sNDA included a third study showing statistical significance, but "FDA decided not to approve Namenda for mild patients based upon this single positive study in light of two previously disclosed, additional studies," Forest said. Namenda would have been the first AD agent approved for the full continuum of the disease. J&J's Risperdal (risperidone) also was deemed not approvable recently for an Alzheimer's-related indication (1Pharmaceutical Approvals Monthly June 2005, p. 13)...
Risperdal "approvable" for autism
Johnson & Johnson's antipsychotic Risperdal (risperidone) is "approvable" for treatment of autism in adolescents and children. The sNDA, submitted Dec. 19, 2003, received a priority review. Risperdal could be the first product approved for autism...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011